MetaVia completes extended Phase 1 study of DA-1726

MetaVia said on November 17, 2026 that the final participant completed the extended Phase 1 Part 3A study of DA-1726. The company extended dosing from 16 to 24 weeks, with participants receiving 48 mg weekly for the additional eight weeks. Previously reported Part 3B interim data showed a statistically significant 68.1% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss. MetaVia expects full Part 3A and 3B results in the first quarter of 2027 and is targeting a Phase 2 study in the second half of 2027.

The update advances DA-1726 toward Phase 2 development while leaving investors awaiting full safety and efficacy results. MetaVia plans a 48-week, non-biopsy Phase 2 study in up to 150 patients with MetALD and ALD, targeted to start in the second half of 2027.

  • 1MetaVia extended Part 3A treatment from 16 to 24 weeks, including an additional eight weeks at 48 mg of DA-1726 weekly.
  • 2Part 3B interim results showed a statistically significant 68.1% placebo-adjusted reduction in liver fat after 16 weeks.
  • 3Part 3B interim results also showed a 13.5% placebo-adjusted reduction in body weight.
  • 4MetaVia expects complete data from Parts 3A and 3B in the first quarter of 2027.
  • 5The planned Phase 2 study is designed to run for 48 weeks and include up to 150 patients with MetALD and ALD.

Sources